Hutchmed (China) Limited
Biopharmaceutical firm developing targeted therapies for cancer and immune diseases.
HCM | HKEX
Overview
Corporate Details
- ISIN(s):
- KYG4672N1198 (+1 more)
- LEI:
- 2138006X34YDQ6OBYE79
- Country:
- Hong Kong
- Address:
- LEVEL 18, THE METROPOLIS TOWER, KOWLOON
- Website:
- https://www.hutch-med.com/
- Sector:
- Manufacturing
Description
Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-09-21 08:00 |
Surufatinib Data at ESMO and in Lancet Oncology
|
English | 32.0 KB | ||
| 2020-09-17 12:45 |
Second Chinese NDA Acceptance for Surufatinib
|
English | 24.2 KB | ||
| 2020-09-04 08:00 |
Chi-Med Initiates Global Phase III Trial
|
English | 23.4 KB | ||
| 2020-09-03 08:00 |
Chi-Med Initiates a Phase II Trial
|
English | 20.8 KB | ||
| 2020-08-28 12:30 |
Total Voting Rights
|
English | 13.1 KB | ||
| 2020-08-24 08:00 |
Clinical Data to be Presented at ESMO 2020
|
English | 26.3 KB | ||
| 2020-08-12 11:30 |
Grant of Share Options under Share Option Scheme
|
English | 18.6 KB | ||
| 2020-08-10 08:00 |
Surufatinib Marketing Authorization Application
|
English | 20.8 KB | ||
| 2020-07-30 13:00 |
Interim Results and Clinical Update
|
English | 775.8 KB | ||
| 2020-07-30 08:00 |
Block Admission Application
|
English | 15.2 KB | ||
| 2020-07-28 08:00 |
Chi-Med & Lilly Collaborate on Elunate in China
|
English | 22.6 KB | ||
| 2020-07-28 08:00 |
Savolitinib NDA Granted Priority Review in China
|
English | 23.3 KB | ||
| 2020-07-24 08:00 |
Chi-Med Initiates HMPL-306 Phase I Trial in China
|
English | 20.5 KB | ||
| 2020-07-08 09:00 |
Holding(s) in Company
|
English | 49.2 KB | ||
| 2020-07-07 09:00 |
Holding(s) in Company
|
English | 88.6 KB |
Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hutchmed (China) Limited
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
